KEGG   DRUG: Etesevimab
Entry
D11944                      Drug                                   
Name
Etesevimab (USAN)
Formula
C6436H9958N1710O2022S48
Exact mass
145089.5550
Mol weight
145179.39
Sequence
(Heavy chain)
EVQLVESGGG LVQPGGSLRL SCAASGFTVS SNYMSWVRQA PGKGLEWVSV IYSGGSTFYA
DSVKGRFTIS RDNSMNTLFL QMNSLRAEDT AVYYCARVLP MYGDYLDYWG QGTLVTVSSA
STKGPSVFPL APSSKSTSGG TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
LYSLSSVVTV PSSSLGTQTY ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPEAAGGP
SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSREEM
TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ
QGNVFSCSVM HEALHNHYTQ KSLSLSPGK
(Light chain)
DIVMTQSPSS LSASVGDRVT ITCRASQSIS RYLNWYQQKP GKAPKLLIYA ASSLQSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ SYSTPPEYTF GQGTKLEIKR TVAAPSVFIF
PPSDEQLKSG TASVVCLLNN FYPREAKVQW KVDNALQSGN SQESVTEQDS KDSTYSLSST
LTLSKADYEK HKVYACEVTH QGLSSPVTKS FNRGEC
(Disulfide bride: H22-H95, H146-H202, H222-L216, H228-H'228, H231-H'231, H263-H323, H369-H427, H'22-H'95, H'146-H'202, H'222-L'216, H'263-H'323, H'369-H'427, L23-L88, L136-L196, L'23-L'88, L'136-L'196)
  Type
Peptide
Class
Antiviral
 DG03174  Anti-SARS-CoV-2 agent
Efficacy
Antiviral
  Disease
Coronavirus disease 2019 [DS:H02398]
  Type
Monoclonal antibody
Comment
Treatment of SARS-CoV-2 Infection (COVID-19)
Target
SARS-CoV-2 spike glycoprotein [KO:K24152]
  Pathway
ko03230  Viral genome structure
ko03262  Virion - Coronavirus
ko05171  Coronavirus disease - COVID-19
  Network
nt06171  SARS coronavirus 2 (SARS-CoV-2)
Brite
Drug groups [BR:br08330]
 Antiviral
  DG03174  Anti-SARS-CoV-2 agent
   D11944  Etesevimab
Antimicrobials [BR:br08307]
 Antivirals
  Entry, fusion or uncoating inhibitor
   Coronavirus spike protein
    D11944  Etesevimab (USAN)
Other DBs
CAS: 2423948-94-9
PubChem: 497620357
LinkDB

» Japanese version   » Back

KEGG   DRUG: Tozinameran
Entry
D11971                      Drug                                   
Name
Tozinameran (JAN);
COVID-19 mRNA vaccine (nucleoside-modified);
Tozinameran and riltozinameran;
Tozinameran and famtozinameran;
Tozinameran and raxtozinameran;
Comirnaty (TN)
Product
COMIRNATY (Pfizer Laboratories Div Pfizer)
Class
Antiviral
 DG03172  COVID-19 vaccine
Remark
Therapeutic category: 6313
ATC code: J07BN01
Product: D11971<JP/US>
Efficacy
Active immunization (SARS-CoV-2)
  Disease
Prevention of COVID-19 [DS:H02398]
Comment
Tozinameran is mRNA encoding full length of spike protein analog of SARS-CoV-2
Target
SARS-CoV-2 spike glycoprotein [KO:K24152]
  Pathway
ko03230  Viral genome structure
ko03262  Virion - Coronavirus
ko05171  Coronavirus disease - COVID-19
  Network
nt06171  SARS coronavirus 2 (SARS-CoV-2)
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J07 VACCINES
   J07B VIRAL VACCINES
    J07BN Covid-19 vaccines
     J07BN01 Covid-19, RNA-based vaccine
      D11971  Tozinameran (JAN) <JP/US>
USP drug classification [BR:br08302]
 Immunological Agents
  Vaccines
   COVID-19
    COVID-19 Vaccine (mRNA)
     D11971  Tozinameran (JAN)
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  63  Biological preparations
   631  Vaccines
    6313  Viral vaccines
     D11971  Tozinameran (JAN)
Drug groups [BR:br08330]
 Antiviral
  DG03172  COVID-19 vaccine
   D11971  Tozinameran
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11971
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11971
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D11971
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11971
Other DBs
CAS: 2417899-77-3
PubChem: 497620384
LinkDB

» Japanese version   » Back

KEGG   DRUG: Sotrovimab
Entry
D12014                      Drug                                   
Name
Sotrovimab (USAN/INN);
Sotrovimab (genetical recombination) (JAN);
Xevudy (TN)
Formula
C6492H10060N1744O2038S40
Exact mass
146340.5997
Mol weight
146430.48
Sequence
(Heavy chain)
QVQLVQSGAE VKKPGASVKV SCKASGYPFT SYGISWVRQA PGQGLEWMGW ISTYQGNTNY
AQKFQGRVTM TTDTSTTTGY MELRRLRSDD TAVYYCARDY TRGAWFGESL IGGFDNWGQG
TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF
PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP
APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK
PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT
LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL
TVDKSRWQQG NVFSCSVLHE ALHSHYTQKS LSLSPGK
(Light chain)
EIVLTQSPGT LSLSPGERAT LSCRASQTVS STSLAWYQQK PGQAPRLLIY GASSRATGIP
DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QHDTSLTFGG GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H96, H154-H210, H230-L214, H236-H'236, H239-H'239, H271-H331, H377-H435, H'22-H'96, H'154-H'210, H'230-L'214, H'271-H'331, H'377-H'435, L23-L89, L134-L194, L'23-L'89, L'134-L'194)
  Type
Peptide
Class
Antiviral
 DG03174  Anti-SARS-CoV-2 agent
Remark
Therapeutic category: 6250
ATC code: J06BD05
Product: D12014<JP>
Efficacy
Antiviral
  Disease
COVID-19 [DS:H02398]
  Type
Monoclonal antibody
Target
SARS-CoV-2 spike glycoprotein [KO:K24152]
  Pathway
ko03230  Viral genome structure
ko03262  Virion - Coronavirus
ko05171  Coronavirus disease - COVID-19
  Network
nt06171  SARS coronavirus 2 (SARS-CoV-2)
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J06 IMMUNE SERA AND IMMUNOGLOBULINS
   J06B IMMUNOGLOBULINS
    J06BD Antiviral monoclonal antibodies
     J06BD05 Sotrovimab
      D12014  Sotrovimab (USAN/INN) <JP>
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  62  Chemotherapeutics
   625  Antivirals
    6250  Antivirals
     D12014  Sotrovimab (USAN/INN); Sotrovimab (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Antiviral
  DG03174  Anti-SARS-CoV-2 agent
   D12014  Sotrovimab
Drug classes [BR:br08332]
 Antiviral
  DG03174  Anti-SARS-CoV-2 agent
   D12014  Sotrovimab
Antimicrobials [BR:br08307]
 Antivirals
  Entry, fusion or uncoating inhibitor
   Coronavirus spike protein
    D12014  Sotrovimab (USAN/INN) <JP>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D12014
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D12014
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D12014
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D12014
Other DBs
CAS: 2423014-07-5
PubChem: 497620427
LinkDB

» Japanese version   » Back

KEGG   DRUG: Elasomeran
Entry
D12114                      Drug                                   
Name
Elasomeran (JAN);
COVID-19 mRNA vaccine (nucleotide modified);
Covid-19 vaccine;
CX-024414;
CX-034476;
Andusomeran (JAN);
Elasomeran (JAN) and imelasomeran (JAN);
Elasomeran (JAN) and davesomeran (JAN);
Moderna Covid-19 vaccine (TN);
Spikevax (TN)
Product
SPIKEVAX (Moderna US)
Class
Antiviral
 DG03172  COVID-19 vaccine
Remark
Therapeutic category: 6313
ATC code: J07BN01
Product: D12114<JP/US>
Efficacy
Active immunization (SARS-CoV-2)
  Disease
Prevention of COVID-19 [DS:H02398]
Target
SARS-CoV-2 spike glycoprotein [KO:K24152]
  Pathway
ko03230  Viral genome structure
ko03262  Virion - Coronavirus
ko05171  Coronavirus disease - COVID-19
  Network
nt06171  SARS coronavirus 2 (SARS-CoV-2)
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J07 VACCINES
   J07B VIRAL VACCINES
    J07BN Covid-19 vaccines
     J07BN01 Covid-19, RNA-based vaccine
      D12114  Elasomeran (JAN) <JP/US>
USP drug classification [BR:br08302]
 Immunological Agents
  Vaccines
   COVID-19
    COVID-19 Vaccine (mRNA)
     D12114  Elasomeran (JAN)
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  63  Biological preparations
   631  Vaccines
    6313  Viral vaccines
     D12114  Elasomeran (JAN); Andusomeran (JAN); Elasomeran (JAN) and imelasomeran (JAN); Elasomeran (JAN) and davesomeran (JAN)
Drug groups [BR:br08330]
 Antiviral
  DG03172  COVID-19 vaccine
   D12114  Elasomeran
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D12114
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D12114
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D12114
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D12114
Other DBs
PubChem: 497620527
LinkDB

» Japanese version   » Back

KEGG   DRUG: COVID-19 vaccine (ChAdOx1-S [recombinant])
Entry
D12115                      Drug                                   
Name
COVID-19 vaccine (ChAdOx1-S [recombinant]);
ChAdOx1-SARS-COV-2;
Vaxzevria (TN)
Class
Antiviral
 DG03172  COVID-19 vaccine
Remark
ATC code: J07BN02
Efficacy
Active immunization (SARS-CoV-2)
  Disease
Prevention of COVID-19 [DS:H02398]
Target
SARS-CoV-2 spike glycoprotein [KO:K24152]
  Pathway
ko03230  Viral genome structure
ko03262  Virion - Coronavirus
ko05171  Coronavirus disease - COVID-19
  Network
nt06171  SARS coronavirus 2 (SARS-CoV-2)
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J07 VACCINES
   J07B VIRAL VACCINES
    J07BN Covid-19 vaccines
     J07BN02 Covid-19, viral vector, non-replicating
      D12115  COVID-19 vaccine (ChAdOx1-S [recombinant])
USP drug classification [BR:br08302]
 Immunological Agents
  Vaccines
   COVID-19
    COVID-19 Vaccine (Subunit)
     D12115  COVID-19 vaccine (ChAdOx1-S [recombinant])
Drug groups [BR:br08330]
 Antiviral
  DG03172  COVID-19 vaccine
   D12115  COVID-19 vaccine (ChAdOx1-S [recombinant])
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D12115
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D12115
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D12115
Other DBs
PubChem: 497620528
LinkDB

» Japanese version   » Back

KEGG   DRUG: COVID-19 vaccine (Ad26.COV2-S [recombinant])
Entry
D12129                      Drug                                   
Name
COVID-19 vaccine (Ad26.COV2-S [recombinant]);
Janssen COVID-19 vaccine;
Ad26.COV2.S;
Covid-19 vaccine Janssen (TN);
Jcovden (TN)
Class
Antiviral
 DG03172  COVID-19 vaccine
Remark
Therapeutic category: 6313
ATC code: J07BN02
Efficacy
Active immunization (SARS-CoV-2)
  Disease
Prevention of COVID-19 [DS:H02398]
Target
SARS-CoV-2 spike glycoprotein [KO:K24152]
  Pathway
ko03230  Viral genome structure
ko03262  Virion - Coronavirus
ko05171  Coronavirus disease - COVID-19
  Network
nt06171  SARS coronavirus 2 (SARS-CoV-2)
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J07 VACCINES
   J07B VIRAL VACCINES
    J07BN Covid-19 vaccines
     J07BN02 Covid-19, viral vector, non-replicating
      D12129  COVID-19 vaccine (Ad26.COV2-S [recombinant])
USP drug classification [BR:br08302]
 Immunological Agents
  Vaccines
   COVID-19
    COVID-19 Vaccine (Subunit)
     D12129  COVID-19 vaccine (Ad26.COV2-S [recombinant])
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  63  Biological preparations
   631  Vaccines
    6313  Viral vaccines
     D12129  COVID-19 vaccine (Ad26.COV2-S [recombinant])
Drug groups [BR:br08330]
 Antiviral
  DG03172  COVID-19 vaccine
   D12129  COVID-19 vaccine (Ad26.COV2-S [recombinant])
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D12129
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D12129
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D12129
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D12129
Other DBs
PubChem: 497620542
LinkDB

» Japanese version   » Back

KEGG   DRUG: Casirivimab and imdevimab
Entry
D12142            Mixture   Drug                                   
Name
Casirivimab and imdevimab;
Casirivimab (genetical recombination) and imdevimab (genetical recombination);
Regen-cov (TN);
Ronapreve (TN)
Component
Casirivimab [DR:D11938], Imdevimab [DR:D11939]
Class
Antiviral
 DG03174  Anti-SARS-CoV-2 agent
Remark
Therapeutic category: 6250
ATC code: J06BD07
Product: D12142<JP>
Efficacy
Antiviral
  Type
Monoclonal antibody combination
Target
SARS-CoV-2 spike glycoprotein [KO:K24152]
  Pathway
ko03230  Viral genome structure
ko03262  Virion - Coronavirus
ko05171  Coronavirus disease - COVID-19
  Network
nt06171  SARS coronavirus 2 (SARS-CoV-2)
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J06 IMMUNE SERA AND IMMUNOGLOBULINS
   J06B IMMUNOGLOBULINS
    J06BD Antiviral monoclonal antibodies
     J06BD07 Casirivimab and imdevimab
      D12142  Casirivimab and imdevimab <JP>
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  62  Chemotherapeutics
   625  Antivirals
    6250  Antivirals
     D12142  Casirivimab and imdevimab
Drug groups [BR:br08330]
 Antiviral
  DG03174  Anti-SARS-CoV-2 agent
   D12142  Casirivimab and imdevimab
Drug classes [BR:br08332]
 Antiviral
  DG03174  Anti-SARS-CoV-2 agent
   D12142  Casirivimab and imdevimab
Antimicrobials [BR:br08307]
 Antivirals
  Entry, fusion or uncoating inhibitor
   Coronavirus spike protein
    D12142  Casirivimab and imdevimab <JP>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D12142
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D12142
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D12142
Other DBs
PubChem: 497620555
LinkDB

» Japanese version   » Back

KEGG   DRUG: Regdanvimab
Entry
D12241                      Drug                                   
Name
Regdanvimab (INN);
Regkirona (TN)
Sequence
(Heavy chain)
QITLKESGPT LVKPTQTLTL TCSFSGFSLS TSGVGVGWIR QPPGKALEWL ALIDWDDNKY
HTTSLKTRLT ISKDTSKNQV VLTMTNMDPV DTATYYCARI PGFLRYRNRY YYYGMDVWGQ
GTTVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT
FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC
PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT
KPREEQYNST YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY
TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK
LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK
(Light chain)
ELVLTQPPSV SAAPGQKVTI SCSGSSSNIG NNYVSWYQQL PGTAPKLLIY DNNKRPSGIP
DRFSGSKSGT SATLGITGLQ TGDEADYYCG TWDSSLSAGV FGGGTELTVL GQPKAAPSVT
LFPPSSEELQ ANKATLVCLI SDFYPGAVTV AWKADGSPVK AGVETTKPSK QSNNKYAASS
YLSLTPEQWK SHRSYSCQVT HEGSTVEKTV APTECS
(Disulfide bridge: H22-H97, H155-H211, H231-L215, H237-H'237, H240-H'240, H272-H332, H378-H436, H'22-H'97, H'155-H'211, H'231-L'215, H'272-H'332, H'378-H'436, L22-L89, L138-L197, L'22-L'89, L'138-L'197)
  Type
Peptide
Class
Antiviral
 DG03174  Anti-SARS-CoV-2 agent
Remark
ATC code: J06BD06
Efficacy
Antiviral
  Type
Monoclonal antibody
Comment
Treatment of adults with coronavirus disease 2019 (COVID-19)
Target
SARS-CoV-2 spike glycoprotein [KO:K24152]
  Pathway
ko03230  Viral genome structure
ko03262  Virion - Coronavirus
ko05171  Coronavirus disease - COVID-19
  Network
nt06171  SARS coronavirus 2 (SARS-CoV-2)
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J06 IMMUNE SERA AND IMMUNOGLOBULINS
   J06B IMMUNOGLOBULINS
    J06BD Antiviral monoclonal antibodies
     J06BD06 Regdanvimab
      D12241  Regdanvimab (INN)
Drug groups [BR:br08330]
 Antiviral
  DG03174  Anti-SARS-CoV-2 agent
   D12241  Regdanvimab
Antimicrobials [BR:br08307]
 Antivirals
  Entry, fusion or uncoating inhibitor
   Coronavirus spike protein
    D12241  Regdanvimab (INN)
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D12241
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D12241
Other DBs
CAS: 2444308-95-4
PubChem: 497620654
LinkDB

» Japanese version   » Back

KEGG   DRUG: SARS-CoV-2 Spike glycoprotein vaccine antigen nvx-cov2373
Entry
D12336                      Drug                                   
Name
SARS-CoV-2 Spike glycoprotein vaccine antigen nvx-cov2373;
SARS-CoV-2 rS;
Novavax Covid-19 vaccine (TN);
Nuvaxovid (TN)
Product
NUVAXOVID COVID-19 VACCINE, ADJUVANTED (Novavax)
Class
Antiviral
 DG03172  COVID-19 vaccine
Remark
Therapeutic category: 6313
ATC code: J07BN04
Product: D12336<JP/US>
Efficacy
Active immunization (SARS-CoV-2)
  Disease
Prevention of COVID-19 [DS:H02398]
Target
SARS-CoV-2 spike glycoprotein [KO:K24152]
  Pathway
ko03230  Viral genome structure
ko03262  Virion - Coronavirus
ko05171  Coronavirus disease - COVID-19
  Network
nt06171  SARS coronavirus 2 (SARS-CoV-2)
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J07 VACCINES
   J07B VIRAL VACCINES
    J07BN Covid-19 vaccines
     J07BN04 Covid-19, protein subunit
      D12336  SARS-CoV-2 Spike glycoprotein vaccine antigen nvx-cov2373 <JP/US>
USP drug classification [BR:br08302]
 Immunological Agents
  Vaccines
   COVID-19
    COVID-19 Vaccine (Subunit)
     D12336  SARS-CoV-2 Spike glycoprotein vaccine antigen nvx-cov2373
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  63  Biological preparations
   631  Vaccines
    6313  Viral vaccines
     D12336  SARS-CoV-2 Spike glycoprotein vaccine antigen nvx-cov2373
Drug groups [BR:br08330]
 Antiviral
  DG03172  COVID-19 vaccine
   D12336  SARS-CoV-2 Spike glycoprotein vaccine antigen nvx-cov2373
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D12336
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D12336
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D12336
Other DBs
PubChem: 497620749
LinkDB

» Japanese version   » Back

KEGG   DRUG: Ufrenmeran
Entry
D12610                      Drug                                   
Name
Ufrenmeran (JAN/INN);
Tegrenmeran (JAN);
Bemremeran (JAN);
MAFB-7256a;
Daichirona (TN)
Class
Antiviral
 DG03172  COVID-19 vaccine
Remark
Therapeutic category: 6313
ATC code: J07BN01
Product: D12610<JP>
Efficacy
Active immunization (SARS-CoV-2)
Target
SARS-CoV-2 spike glycoprotein [KO:K24152]
  Pathway
ko03230  Viral genome structure
ko03262  Virion - Coronavirus
ko05171  Coronavirus disease - COVID-19
  Network
nt06171  SARS coronavirus 2 (SARS-CoV-2)
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J07 VACCINES
   J07B VIRAL VACCINES
    J07BN Covid-19 vaccines
     J07BN01 Covid-19, RNA-based vaccine
      D12610  Ufrenmeran (JAN/INN) <JP>
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  63  Biological preparations
   631  Vaccines
    6313  Viral vaccines
     D12610  Ufrenmeran (JAN/INN); Tegrenmeran (JAN); Bemremeran (JAN)
Drug groups [BR:br08330]
 Antiviral
  DG03172  COVID-19 vaccine
   D12610  Ufrenmeran
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D12610
Other DBs
CAS: 2749556-96-3
PubChem: 497621023
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system